Citalopram ( DrugBank: Citalopram )

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2
13	Multiple sclerosis/Neuromyelitis optica	1

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04497168 (ClinicalTrials.gov)	April 1, 2021	29/7/2020	Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease	Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease	Parkinson Disease	Drug: Citalopram 20mg;Drug: Placebo	University of Michigan	National Institute on Aging (NIA)	Recruiting	65 Years	N/A	All	58	Phase 2	United States
2	NCT04590612 (ClinicalTrials.gov)	January 2021	17/9/2020	Improving Quality of Life in Early Parkinson's Disease	The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients	Parkinson Disease;Depression	Drug: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet;Drug: Citalopram	Western University, Canada	NULL	Not yet recruiting	50 Years	80 Years	All	30	N/A	NULL

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01436643 (ClinicalTrials.gov)	November 2011	16/9/2011	Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression	A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression	Depression;Relapsing-remitting Multiple Sclerosis	Drug: Venlafaxine;Drug: Fluoxetine;Drug: Citalopram;Drug: Fingolimod	Novartis Pharmaceuticals	NULL	Terminated	18 Years	65 Years	All	54	Phase 4	Germany